Western blot analysis of extracts from serum-starved HT-1080 cells, untreated and treated for 30 minutes with various concentrations of Human BMP-2, using Phospho-Smad1/5 (Ser463/465) (41D10) Rabbit mAb #9516 (upper) and Smad1 Antibody #9743 (lower).Learn more about how we get our images
Recombinant human BMP-2 was expressed in E. coli and is supplied in a lyophilized form. A greater than 95% purity was determined by reverse-phase HPLC and SDS-PAGE.
The ED50 as determined by the cytolysis of MC3T3-E1 cells is less than 50 ng/ml.
The working concentration of BMP-2 generally ranges from 20-50 ng/ml.
Lyophilized product is very stable at -20°C. It is recommended to reconstitute with 10 mM HCl at a concentration of 0.1 mg/ml, which can be further diluted in aqueous solutions as needed. Addition of a carrier protein (0.1% HSA or BSA) is recommended for long-term storage.
Bone morphogenetic proteins (BMPs) were first identified as molecules that can induce ectopic bone and cartilage formation (1,2). BMPs are synthesized as precursor proteins that are processed by cleavage to produce mature proteins. BMPs initiate signaling by binding to a receptor complex containing type I and type II serine/threonine receptor kinases that then phosphorylate Smad (mainly Smad1, 5 and 8), resulting in the translocation of Smad to the nucleus. BMP was also reported to activate MAPK pathways in some systems (3,4).
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
Explore pathways related to this product.
|4697S||10 µg||$ 276.0|